Nascent Biotech completes Phase 1 clinical trial for pritumumab

Nascent Biotech has completed and closed its Phase I clinical trial evaluating safety and tolerance for Pritumumab as a treatment for Primary and Metastatic Brain Cancers. Previous announcements shared the end of the enrollment and dosing period of the Phase I trial. Nascent will continue to collect and evaluate the Clinical data from the Phase I trial as it prepares to submit results to the U.S. FDA for Phase II consideration. Completing the Phase I trial is a major milestone and Nascent is excited to move toward finalizing plans for Phase II research. Phase I reinforced the companies’ determination and excitement around this unique monoclonal antibody treatment approach and Phase I has shown that it can be given safely at high doses. This is a new pathway toward attacking one of the defining health challenges we face, with longer-term implications that transcend the brain cancer market. We look forward to the opportunity to see our unique R&D platform become a game changer for patients suffering from brain cancer.